GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Enterprise Value

Shanghai Henlius Biotech (HKSE:02696) Enterprise Value : HK$15,744 Mil (As of Dec. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shanghai Henlius Biotech's Enterprise Value is HK$15,744 Mil. Shanghai Henlius Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$414 Mil. Therefore, Shanghai Henlius Biotech's EV-to-EBIT ratio for today is 38.05.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Shanghai Henlius Biotech's Enterprise Value is HK$15,744 Mil. Shanghai Henlius Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$627 Mil. Therefore, Shanghai Henlius Biotech's EV-to-EBITDA ratio for today is 25.10.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Shanghai Henlius Biotech's Enterprise Value is HK$15,744 Mil. Shanghai Henlius Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$3,136 Mil. Therefore, Shanghai Henlius Biotech's EV-to-Revenue ratio for today is 5.02.


Shanghai Henlius Biotech Enterprise Value Historical Data

The historical data trend for Shanghai Henlius Biotech's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Enterprise Value Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 20,264.98 26,233.91 15,006.00 10,303.10 10,951.19

Shanghai Henlius Biotech Quarterly Data
Dec17 Mar18 Jun18 Dec18 Mar19 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,303.10 9,480.45 9,248.86 10,951.19 16,084.10

Competitive Comparison of Shanghai Henlius Biotech's Enterprise Value

For the Biotechnology subindustry, Shanghai Henlius Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Enterprise Value falls into.



Shanghai Henlius Biotech Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Shanghai Henlius Biotech's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Shanghai Henlius Biotech's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Henlius Biotech  (HKSE:02696) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Shanghai Henlius Biotech's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15743.661/413.794
=38.05

Shanghai Henlius Biotech's current Enterprise Value is HK$15,744 Mil.
Shanghai Henlius Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$414 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Shanghai Henlius Biotech's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=15743.661/627.29
=25.10

Shanghai Henlius Biotech's current Enterprise Value is HK$15,744 Mil.
Shanghai Henlius Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$627 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Shanghai Henlius Biotech's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=15743.661/3135.798
=5.02

Shanghai Henlius Biotech's current Enterprise Value is HK$15,744 Mil.
Shanghai Henlius Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$3,136 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Henlius Biotech Enterprise Value Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Qatar Investment Authority 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you
Jiang Wei-dong 2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc. 2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines